Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
However, an analysis of Swiss people with HIV found no significant change in the suicide rate in more recent years.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.
A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
However, Tivicay plus Descovy was associated with greater weight gain, especially among women.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Changes include new information about risks associated with dolutegravir during pregnancy and removal of older drugs owing to toxicities.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
Researchers examined outcomes among a group of people in middle- and low-income nations who switched to the integrase inhibitor.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
Tivicay was associated with a higher rate of viral suppression at delivery compared with Sustiva.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
Timothy Brown may have company after a man’s virus went into remission following an HIV-resistant stem cell transplant to treat his cancer.
Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.
This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.